BioDelivery Sciences (BDSI) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BioDelivery Sciences Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results
March 17, 2017 6:30 AM EDTRALEIGH, N.C., March 17, 2017 /PRNewswire/ --Â BioDelivery Sciences International, Inc. (BDSI) today reported financial results for the fourth quarter and full year ended December 31, 2016, and provided an update on recent business highlights and upcoming milestones.
In January 2017, BDSI reacquired worldwide rights to BELBUCA® (buprenorphine) buccal film (CIII) from Endo Pharmaceuticals. The transfer of worldwide rights back to BDSI followed a strategic decision announced by Endo in December 2016 to discontinue commercial efforts for the U.S. branded pain business. Based on the agreement, BDSI will... More
